The Medicines Company Company Profile (NASDAQ:MDCO)

About The Medicines Company

The Medicines Company logoThe Medicines Company is a global biopharmaceutical company. The Company's marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). Its pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. It sells a ready to use formulation of Argatroban and has a portfolio of over 10 generic drugs, which is referred as acute care generic products. It sells over three acute care generic products, including midazolam, ondansetron and rocuronium. The Company's products include Angiomax, which is a direct thrombin inhibitor; Cleviprex, which is a calcium channel blocker; Ionsys, which is a patient-controlled analgesia system; Kengreal, which is an antiplatelet agent; Minocin IV, which is a tetracycline-class antibiotic, and Orbactiv, which is an antibiotic.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: MDCO
  • CUSIP: 58468810
Key Metrics:
  • Previous Close: $52.06
  • 50 Day Moving Average: $42.42
  • 200 Day Moving Average: $38.01
  • 52-Week Range: $29.48 - $54.01
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.15
  • P/E Growth: -0.51
  • Market Cap: $3.65B
  • Outstanding Shares: 70,194,000
  • Beta: 0.5
Profitability:
  • Net Margins: -96.44%
  • Return on Equity: -35.07%
  • Return on Assets: -14.80%
Debt:
  • Debt-to-Equity Ratio: 0.81%
  • Current Ratio: 3.46%
  • Quick Ratio: 3.12%
Additional Links:
Companies Related to The Medicines Company:

Analyst Ratings

Consensus Ratings for The Medicines Company (NASDAQ:MDCO) (?)
Ratings Breakdown: 2 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $53.13 (2.05% upside)

Analysts' Ratings History for The Medicines Company (NASDAQ:MDCO)
Show:
DateFirmActionRatingPrice TargetDetails
1/8/2017Chardan CapitalReiterated RatingBuy$65.00View Rating Details
1/6/2017Jefferies Group LLCReiterated RatingPositive$49.00View Rating Details
12/5/2016HC WainwrightInitiated CoverageBuy$57.00View Rating Details
11/18/2016GuggenheimReiterated RatingBuyView Rating Details
11/16/2016Royal Bank of CanadaBoost Price TargetOutperform$45.00 -> $52.00View Rating Details
11/16/2016RBC Capital MarketsBoost Price TargetOutperform$45.00 -> $52.00View Rating Details
11/8/2016Leerink SwannReiterated RatingOutperform$53.00 -> $50.00View Rating Details
10/6/2016J P Morgan Chase & CoReiterated RatingBuyView Rating Details
8/5/2016Cowen and CompanyReiterated RatingBuy$45.00View Rating Details
8/2/2016Citigroup Inc.Reiterated RatingHoldView Rating Details
7/12/2016Bank of America CorpReiterated RatingBuyView Rating Details
3/24/2016Oppenheimer Holdings, Inc.Reiterated RatingHoldView Rating Details
11/6/2015Piper Jaffray CompaniesReiterated RatingNeutral$28.00 -> $31.00View Rating Details
7/6/2015MizuhoUpgradeNeutral -> Buy$28.00 -> $41.00View Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for The Medicines Company (NASDAQ:MDCO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017Q416($1.43)$26.91 millionN/AView Earnings Details
10/26/2016Q316($1.30)($0.64)$37.26 million$37.60 millionViewListenView Earnings Details
7/27/2016Q216($1.16)($0.62)$41.93 million$54.70 millionViewListenView Earnings Details
5/9/2016Q116($0.89)($1.03)$48.96 million$50.30 millionViewListenView Earnings Details
2/17/2016Q415($1.54)($0.88)$64.11 million$67.20 millionViewN/AView Earnings Details
11/3/2015Q315($0.88)($0.82)$68.58 million$72.70 millionViewListenView Earnings Details
7/29/2015Q215($0.20)($0.65)$122.58 million$90.50 millionViewListenView Earnings Details
5/5/2015Q115($0.68)($0.02)$138.78 million$126.50 millionViewListenView Earnings Details
2/18/2015Q414($0.82)$0.20$191.00 millionViewListenView Earnings Details
10/22/2014Q314($0.12)$0.18$188.30 million$172.40 millionViewListenView Earnings Details
7/23/2014Q214($0.02)($0.08)$183.75 million$183.80 millionViewListenView Earnings Details
4/23/2014Q114($0.07)($0.08)$175.60 million$177.20 millionViewListenView Earnings Details
2/19/2014Q413$0.11$0.26$182.60 million$185.00 millionViewListenView Earnings Details
10/23/2013Q313$0.24$0.47$173.86 million$173.45 millionViewListenView Earnings Details
7/24/2013Q2 2013$0.33$0.50$168.70 million$172.00 millionViewListenView Earnings Details
4/24/2013Q1 2013($0.26)$0.31$152.63 million$155.80 millionViewListenView Earnings Details
2/20/2013Q4 2012$0.28$0.38$146.09 million$159.50 millionViewListenView Earnings Details
10/24/2012$0.39$0.40ViewN/AView Earnings Details
7/25/2012$0.22$0.46ViewN/AView Earnings Details
4/25/2012$0.14$0.27ViewN/AView Earnings Details
2/22/2012$0.24$0.52ViewN/AView Earnings Details
10/26/2011$0.20$0.17ViewN/AView Earnings Details
7/27/2011$0.31$0.21ViewN/AView Earnings Details
4/27/2011$0.40$0.45ViewN/AView Earnings Details
2/16/2011$0.24$0.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for The Medicines Company (NASDAQ:MDCO)
Current Year EPS Consensus Estimate: $-1.39 EPS
Next Year EPS Consensus Estimate: $-4.67 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.00)($0.76)($0.85)
Q2 20165($1.39)($0.74)($1.10)
Q3 20165($1.40)($0.76)($1.09)
Q4 20163($1.52)($1.40)($1.46)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for The Medicines Company (NASDAQ:MDCO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for The Medicines Company (NASDAQ:MDCO)
Insider Ownership Percentage: 7.90%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/7/2017William Bernard O'connorCFOSell25,833$46.20$1,193,484.60View SEC Filing  
12/8/2016Christopher T CoxEVPBuy105,500$33.20$3,502,600.00View SEC Filing  
12/8/2016Fredric N EshelmanDirectorBuy621,720$33.77$20,995,484.40View SEC Filing  
9/21/2016Clive MeanwellCEOSell8,623$40.00$344,920.00View SEC Filing  
9/1/2016Clive MeanwellCEOSell1,377$40.00$55,080.00View SEC Filing  
8/24/2016Clive MeanwellCEOSell20,000$40.00$800,000.00View SEC Filing  
7/11/2016Hiroaki ShigetaDirectorSell3,849$38.50$148,186.50View SEC Filing  
6/10/2016Christopher T CoxEVPBuy45,985$37.90$1,742,831.50View SEC Filing  
6/7/2016Christopher T CoxEVPBuy53,340$37.55$2,002,917.00View SEC Filing  
5/24/2016Melvin K SpigelmanDirectorSell15,000$37.00$555,000.00View SEC Filing  
5/16/2016Clive MeanwellCEOSell10,000$35.00$350,000.00View SEC Filing  
5/16/2016William CrouseDirectorSell15,000$35.15$527,250.00View SEC Filing  
5/13/2016Elizabeth H S WyattDirectorSell15,000$34.07$511,050.00View SEC Filing  
5/12/2016Fredric N EshelmanDirectorBuy300,000$33.68$10,104,000.00View SEC Filing  
3/7/2016Armin M KesslerDirectorSell8,100$34.82$282,042.00View SEC Filing  
11/13/2015Robert G. SavageDirectorSell5,000$39.34$196,700.00View SEC Filing  
9/3/2015Glenn SblendorioCFOSell25,000$42.00$1,050,000.00View SEC Filing  
8/31/2015Clive MeanwellCEOSell49,998$39.36$1,967,921.28View SEC Filing  
8/31/2015Glenn SblendorioCFOSell114,495$39.75$4,551,176.25View SEC Filing  
8/31/2015Melvin K. SpigelmanDirectorSell20,000$40.50$810,000.00View SEC Filing  
8/31/2015William Bernard O'connorSVPSell35,451$40.00$1,418,040.00View SEC Filing  
7/1/2015Clive MeanwellCEOSell16,667$28.39$473,176.13View SEC Filing  
6/25/2015Glenn SblendorioCFOSell3,305$32.00$105,760.00View SEC Filing  
6/8/2015Hiroaki ShigetaDirectorSell7,500$28.99$217,425.00View SEC Filing  
5/20/2015Robert G SavageDirectorSell15,000$26.78$401,700.00View SEC Filing  
4/16/2015William Bernard O'connorSVPSell1,281$30.00$38,430.00View SEC Filing  
4/1/2015Clive MeanwellCEOSell16,667$27.58$459,675.86View SEC Filing  
3/30/2015Elizabeth H S WyattDirectorSell20,000$28.08$561,600.00View SEC Filing  
3/23/2015Clive MeanwellCEOSell16,667$30.62$510,343.54View SEC Filing  
3/23/2015Glenn SblendorioCFOSell34,773$30.78$1,070,312.94View SEC Filing  
3/2/2015William Bernard O'connorSVPSell2,988$28.78$85,994.64View SEC Filing  
3/3/2014William Bernard O'connorSVPSell2,968$30.31$89,960.08View SEC Filing  
1/21/2014Paul Michael AntinoriVPSell37,883$38.02$1,440,311.66View SEC Filing  
1/15/2014William Bernard O'connorSVPSell4,427$39.15$173,317.05View SEC Filing  
1/10/2014William Bernard O'connorSVPSell72,384$40.00$2,895,360.00View SEC Filing  
1/7/2014Clive MeanwellCEOSell27,929$38.13$1,064,932.77View SEC Filing  
1/3/2014Clive MeanwellCEOSell57,516$38.16$2,194,810.56View SEC Filing  
12/9/2013William CrouseDirectorSell12,500$38.00$475,000.00View SEC Filing  
12/5/2013Glenn SblendorioCFOSell8,516$38.50$327,866.00View SEC Filing  
12/2/2013Clive MeanwellCEOSell10,000$36.58$365,800.00View SEC Filing  
11/26/2013Clive MeanwellCEOSell135,000$36.70$4,954,500.00View SEC Filing  
10/23/2013William Bernard O'connorSVPSell6,354$35.00$222,390.00View SEC Filing  
9/13/2013Paul Michael AntinoriVPSell73,500$34.50$2,535,750.00View SEC Filing  
9/3/2013Clive MeanwellCEOSell7,500$31.85$238,875.00View SEC Filing  
8/1/2013Clive MeanwellCEOSell7,500$31.26$234,450.00View SEC Filing  
7/8/2013Paul Michael AntinoriVPSell36,000$33.00$1,188,000.00View SEC Filing  
7/1/2013Clive MeanwellCEOSell7,500$31.25$234,375.00View SEC Filing  
6/11/2013Paul Michael AntinoriVPSell109,973$33.29$3,661,001.17View SEC Filing  
5/29/2013Armin M KesslerDirectorSell8,750$33.05$289,187.50View SEC Filing  
5/10/2013Glenn SblendorioCFOSell2,709$37.00$100,233.00View SEC Filing  
5/9/2013Paul Michael AntinoriVPSell35,000$34.90$1,221,500.00View SEC Filing  
5/9/2013William Bernard O'connorSVPSell29,654$35.00$1,037,890.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for The Medicines Company (NASDAQ:MDCO)
DateHeadline
feeds.benzinga.com logoEarth Science Tech Initiates its Cannabis Cannabinoid-Based Composition of its 2 New Pharmaceutical Drugs and 3 Nutraceutical Patent Studies (NASDAQ:MDCO)
feeds.benzinga.com - February 23 at 7:42 AM
News IconFiscal Year Earnings Estimate on The Medicines Company(MDCO) - Money Flow Index & Trends (NASDAQ:MDCO)
www.moneyflowtrends.com - February 23 at 7:08 AM
News IconWhy Investors remained confident on The Medicines Company (MDCO), Live Nation Entertainment, Inc. (LYV)? - StockNewsJournal (NASDAQ:MDCO)
stocknewsjournal.com - February 23 at 7:08 AM
News IconStock Price of The Medicines Company (MDCO) Increases 5.35% - Highland Mirror (NASDAQ:MDCO)
www.highlandmirror.com - February 22 at 8:14 AM
businesswire.com logoThe Medicines Company Announces FDA Filing Acceptance of New Drug Application for Intravenous Antibiotic ... - Business Wire (press release) (NASDAQ:MDCO)
www.businesswire.com - February 22 at 8:14 AM
streetinsider.com logoMedicines Co. (MDCO) Announces FDA Filing Acceptance of NDA for Intravenous Antibiotic Carbavance (NASDAQ:MDCO)
www.streetinsider.com - February 21 at 6:28 PM
finance.yahoo.com logoThe Medicines Company Announces FDA Filing Acceptance of New Drug Application for Intravenous Antibiotic Carbavance® (meropenem-vaborbactam) (NASDAQ:MDCO)
finance.yahoo.com - February 21 at 6:28 PM
finance.yahoo.com logo7:16 am The Medicines Co: FDA has accepted for priority review its NDA filing for Carbavance for the treatment of complicated UTIs; FDA does not currently plan to hold an advisory committee meeting to discuss the application (NASDAQ:MDCO)
finance.yahoo.com - February 21 at 6:28 PM
businesswire.com logoThe Medicines Company to Announce Fourth-Quarter and Full-Year 2016 Financial Results on February 28, 2017 - Business Wire (press release) (NASDAQ:MDCO)
www.businesswire.com - February 18 at 5:43 PM
News IconWhat is the Sell-side Saying About The Medicines Company (NASDAQ:MDCO)? - Aiken Advocate (NASDAQ:MDCO)
aikenadvocate.com - February 17 at 7:24 PM
News IconThe Medicines Company (MDCO): The Technicals As Seen Today - NY Stock News (NASDAQ:MDCO)
nystocknews.com - February 17 at 2:24 PM
finance.yahoo.com logoThe Medicines Company to Announce Fourth-Quarter and Full-Year 2016 Financial Results on February 28, 2017 (NASDAQ:MDCO)
finance.yahoo.com - February 17 at 2:24 PM
News IconLookout for Price Target? Exact Sciences Corporation (EXAS), The Medicines Company (MDCO) (NASDAQ:MDCO)
giftedviz.com - February 14 at 8:01 PM
News IconToday's Brokerage Rating: Dick's Sporting Goods, Inc. (DKS), The Medicines Company (MDCO) - StockNewsJournal (NASDAQ:MDCO)
stocknewsjournal.com - February 11 at 5:21 AM
fool.com logoAlnylam Pharmaceuticals, Inc. Presents Progress -- Investors Dig It (NASDAQ:MDCO)
www.fool.com - February 9 at 7:29 PM
News IconEquity Sheet: Reviewing the Levels for The Medicines Company (NASDAQ:MDCO) - Baldwin Journal (NASDAQ:MDCO)
baldwinjournal.com - February 9 at 12:20 AM
News IconBuy or Sell? Average Brokerage Ratings on The Medicines Company (MDCO), Retail Properties of America, Inc. (RPAI) - StockNewsJournal (NASDAQ:MDCO)
stocknewsjournal.com - February 9 at 12:20 AM
News IconDrilling Down Into The Medicines Company (MDCO) - StockNewsJournal (NASDAQ:MDCO)
stocknewsjournal.com - February 8 at 12:52 AM
News IconThe Medicines Company (NASDAQ:MDCO)- Most Active Trio on Investment Estimation: Axovant Sciences (NYSE:AXON) - Street Wise Report (press release) (blog) (NASDAQ:MDCO)
streetwisereport.com - February 6 at 11:36 PM
seekingalpha.com logoThe Medicines Company: New Entrant In Cholesterol Drug Wars? (NASDAQ:MDCO)
seekingalpha.com - February 6 at 6:35 PM
istreetwire.com logoStocks in the Spotlight: Whiting Petroleum Corporation (WLL), The Medicines Company (MDCO), Exelixis, Inc. (EXEL) - iStreetWire (NASDAQ:MDCO)
istreetwire.com - February 6 at 9:57 AM
News IconLooking at the Tea Leaves for The Medicines Company (MDCO) - The USA Commerce (NASDAQ:MDCO)
theusacommerce.com - February 6 at 9:57 AM
seekingalpha.com logoMarketplace Roundtable: Following Insiders - Seeking Alpha (NASDAQ:MDCO)
seekingalpha.com - February 4 at 11:31 PM
fool.com logoWhy The Medicines Company Rocketed Higher Today - Motley Fool (NASDAQ:MDCO)
www.fool.com - February 4 at 5:11 AM
fool.com logoWhy The Medicines Company Rocketed Higher Today (NASDAQ:MDCO)
www.fool.com - February 3 at 7:09 PM
finance.yahoo.com logoAmgen CEO: Will work with Trump to lower drug prices (NASDAQ:MDCO)
finance.yahoo.com - February 2 at 7:17 PM
News IconThe European Medicines Agency (EMA) Recommends KEYTRUDA From Merck & Co., Inc. (MRK) (NASDAQ:MDCO)
feedproxy.google.com - February 1 at 2:43 PM
News IconAre Insiders Bumping Up Their Positions in The Medicines Company (NASDAQ:MDCO) - Wall Street Beacon (NASDAQ:MDCO)
wsbeacon.com - February 1 at 5:27 AM
News IconEarnings Parade Rolls On, What Are Analysts Saying About The Medicines Company (NASDAQ:MDCO)? - Wall Street Beacon (NASDAQ:MDCO)
wsbeacon.com - February 1 at 5:27 AM
News IconKeeping Tabs on Levels for The Medicines Company (NASDAQ:MDCO) - The Tribune (NASDAQ:MDCO)
lakecitytribune.com - January 29 at 11:55 PM
News IconVC Score In Focus for The Medicines Company (NASDAQ:MDCO) - The Tribune (NASDAQ:MDCO)
lakecitytribune.com - January 29 at 4:39 AM
News IconTrading Indicator Check on The Medicines Company (MDCO) - Springdale Times (NASDAQ:MDCO)
springdaletimes.com - January 29 at 4:39 AM
News IconTrading Lines in Focus for The Medicines Company (MDCO) - Springdale Times (NASDAQ:MDCO)
springdaletimes.com - January 28 at 4:54 AM
News IconWhat is the Street Saying About The Medicines Company (NASDAQ:MDCO)? - Aiken Advocate (NASDAQ:MDCO)
aikenadvocate.com - January 28 at 4:54 AM
streetinsider.com logoMedicines Co. (MDCO) to Present Results from ORION-1 Phase 2 Study of Inclisiran at ACC (NASDAQ:MDCO)
www.streetinsider.com - January 25 at 7:53 PM
businesswire.com logoThe Medicines Company to Present Results from ORION-1 Phase 2 Study of Inclisiran at the American College of Cardiology’s 66 th Annual Scientific Session (NASDAQ:MDCO)
www.businesswire.com - January 25 at 7:53 PM
finance.yahoo.com logoThe Medicines Company to Present Results from ORION-1 Phase 2 Study of Inclisiran at the American College of Cardiology’s 66th Annual Scientific Session (NASDAQ:MDCO)
finance.yahoo.com - January 25 at 7:53 PM
News IconEarnings in Full Force, Analysts Take Aim at The Medicines Company (NASDAQ:MDCO) - Wall Street Beacon (NASDAQ:MDCO)
wsbeacon.com - January 24 at 7:12 PM
News IconTrading Scope: Indicator Review for The Medicines Company (MDCO) - Springdale Times (NASDAQ:MDCO)
springdaletimes.com - January 24 at 7:11 PM
capitalcube.com logoThe Medicines Co. breached its 50 day moving average in a Bearish Manner : MDCO-US : January 23, 2017 (NASDAQ:MDCO)
www.capitalcube.com - January 23 at 10:18 AM
News IconThe Medicines Company MDCO Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:MDCO)
www.bioportfolio.com - January 22 at 4:16 AM
capitalcube.com logoETFs with exposure to The Medicines Co. : January 20, 2017 (NASDAQ:MDCO)
www.capitalcube.com - January 20 at 7:13 PM
News IconThe Medicines Company (NASDAQ:MDCO) hit its 52 Week low of ... - The Newburgh Press (NASDAQ:MDCO)
newburghpress.com - January 19 at 8:28 PM
News IconWill The Needle Move For The Medicines Company (NASDAQ:MDCO) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:MDCO)
wsbeacon.com - January 18 at 4:51 AM
seekingalpha.com logoThe Medicines Company May Break Out With Inclisiran (NASDAQ:MDCO)
seekingalpha.com - January 17 at 6:49 PM
realistinvestor.com logoQuarterly Deferred Tax Assets Of The Medicines Company (NASDAQ:MDCO) At $33.08 Millions (NASDAQ:MDCO)
www.realistinvestor.com - January 16 at 7:02 PM
realistinvestor.com logoQuarterly Deferred Tax Assets Of The Medicines Company (NASDAQ:MDCO) At $33.08 Millions - RealistInvestor.com (NASDAQ:MDCO)
www.realistinvestor.com - January 11 at 12:23 AM
businesswire.com logoThe Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 ... - Business Wire (press release) (NASDAQ:MDCO)
www.businesswire.com - January 11 at 12:23 AM
us.rd.yahoo.com logo4:04 am The Medicines Co presents compelling safety and efficacy data from Day 180 interim analysis for ORION-1 Phase 2 Study of Inclisiran (NASDAQ:MDCO)
us.rd.yahoo.com - January 9 at 7:12 PM
News IconThe Medicines Company MDCO Medical Equipment Deals and Alliances Profile Prices from USD $250 (NASDAQ:MDCO)
www.bioportfolio.com - January 8 at 6:11 PM

Social

What is The Medicines Company's stock symbol?

The Medicines Company trades on the NASDAQ under the ticker symbol "MDCO."

Where is The Medicines Company's stock going? Where will The Medicines Company's stock price be in 2017?

12 brokerages have issued 1 year target prices for The Medicines Company's stock. Their forecasts range from $45.00 to $65.00. On average, they anticipate The Medicines Company's share price to reach $53.13 in the next year.

When will The Medicines Company announce their earnings?

The Medicines Company is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.

Who owns The Medicines Company stock?

The Medicines Company's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (15.13%), State Street Corp (2.93%), Sarissa Capital Management LP (2.50%), Dimensional Fund Advisors LP (2.09%), Franklin Resources Inc. (2.03%) and Pinnacle Associates Ltd. (1.96%). Company insiders that own The Medicines Company stock include Armin M Kessler, Christopher T Cox, Clive Meanwell, Elizabeth H S Wyatt, Fredric N Eshelman, Glenn Sblendorio, Hiroaki Shigeta, Melvin K Spigelman, Robert G Savage, William Bernard O'connor and William Crouse.

Who sold The Medicines Company stock? Who is selling The Medicines Company stock?

The Medicines Company's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Federated Investors Inc. PA, Numeric Investors LLC, Fred Alger Management Inc., Dimensional Fund Advisors LP, Teachers Retirement System of The State of Kentucky, Guggenheim Capital LLC and Franklin Resources Inc.. Company insiders that have sold The Medicines Company stock in the last year include Armin M Kessler, Clive Meanwell, Elizabeth H S Wyatt, Hiroaki Shigeta, Melvin K Spigelman, William Bernard O'connor and William Crouse.

Who bought The Medicines Company stock? Who is buying The Medicines Company stock?

The Medicines Company's stock was bought by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, Iridian Asset Management LLC CT, Pinnacle Associates Ltd., Renaissance Technologies LLC, Marshall Wace LLP, RTW Investments LP, Frontier Capital Management Co. LLC and Broadfin Capital LLC. Company insiders that have bought The Medicines Company stock in the last two years include Christopher T Cox and Fredric N Eshelman.

How do I buy The Medicines Company stock?

Shares of The Medicines Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of The Medicines Company stock cost?

One share of The Medicines Company stock can currently be purchased for approximately $52.06.

The Medicines Company (NASDAQ:MDCO) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for The Medicines Company (NASDAQ:MDCO)

Earnings History Chart

Earnings by Quarter for The Medicines Company (NASDAQ:MDCO)

Dividend History Chart

Dividend Payments by Quarter for The Medicines Company (NASDAQ:MDCO)

Last Updated on 2/26/2017 by MarketBeat.com Staff